Suppr超能文献

口服 A1-R 靶向药物可准确、安全地靶向肿瘤,导致裸鼠侵袭性纤维肉瘤消退。

Accurate and Safe Tumor Targeting of Orally-administered A1-R Leads to Regression of an Aggressive Fibrosarcoma in Nude Mice.

机构信息

AntiCancer Inc., San Diego, CA, U.S.A.

Department of Surgery, University of California, San Diego, CA, U.S.A.

出版信息

In Vivo. 2024 Nov-Dec;38(6):2601-2609. doi: 10.21873/invivo.13736.

Abstract

BACKGROUND/AIM: Salmonella typhimurium A1-R has been shown to target and inhibit many types of cancers in mouse models without continuous infection of normal tissue. The objective of the present study was to determine the effective dose of orally-administered Salmonella typhimurium A1-R, expressing-green fluorescent protein (GFP), on an HT1080 human-fibrosarcoma nude-mouse model.

MATERIALS AND METHODS

The HT1080-human- fibrosarcoma nude-mouse models were randomized into the following three groups: G1: untreated control; G2: Oral Salmonella typhimurium A1-R (5×10 colony forming units [CFU]/body, twice a week, 2 weeks); G3: Oral Salmonella typhimurium A1-R (3.3×10 CFU/body, twice a week, 2 weeks). Each group comprised five mice. Body weight and tumor volume were measured twice a week. The number of colonies of Salmonella typhimurium A1-R-GFP in excised tumors and excised livers in groups G2 and G3 were determined on day 3, day 7 and 14 by growth on agar plates. Tukey-Kramer analysis was used to examine the relationships between variables. Statistically-significant results are defined as those with p≤0.05.

RESULTS

Salmonella typhimurium A1-R was administered orally at a dose of 3.3×10 CFU, which successfully regressed the HT1080 tumor in nude mice. However, this effect was not observed at a lower dose of 5×10 CFU. After administering Salmonella typhimurium A1-R at 3.3×10 CFU, tumors and liver tissues were harvested, homogenized, and cultured on days 3, 7 and 14. Resulting GFP-expressing Salmonella typhimurium A1-R colonies were then counted. The number of GFP-bacterial colonies derived from excised tumors at intervals of 3, 7, and 14 days increased over time post-administration of oral GFP-Salmonella typhimurium. Conversely, the number of GFP-Salmonella typhimurium A1-R colonies that could be grown from excised livers decreased over time, following oral administration of GFP-Salmonella typhimurium. Additionally, the GFP-bacterial colonies grown from the excised tumors were significantly larger than those grown from the excised livers.

CONCLUSION

The present study showed that an aggressive fibrosarcoma could be regressed by orally-administered Salmonella typhimurium A1-R which accurately targeted tumors without continuous growth in normal organs. The present results suggested the potential of orally-administered Salmonella typhimurium A1-R as a probiotic to treat aggressive soft-tissue sarcoma.

摘要

背景/目的:鼠伤寒沙门氏菌 A1-R 已被证明可在不持续感染正常组织的情况下靶向和抑制多种类型的癌症,在小鼠模型中。本研究的目的是确定口服表达绿色荧光蛋白 (GFP) 的鼠伤寒沙门氏菌 A1-R 在 HT1080 人纤维肉瘤裸鼠模型中的有效剂量。

材料和方法

HT1080 人纤维肉瘤裸鼠模型随机分为以下三组:G1:未处理对照;G2:口服鼠伤寒沙门氏菌 A1-R(5×10 集落形成单位 [CFU]/体,每周两次,持续 2 周);G3:口服鼠伤寒沙门氏菌 A1-R(3.3×10 CFU/体,每周两次,持续 2 周)。每组包含 5 只小鼠。每周测量两次体重和肿瘤体积。通过琼脂平板培养,在第 3、7 和 14 天测定 G2 和 G3 组中切除肿瘤和切除肝脏中 GFP 表达鼠伤寒沙门氏菌 A1-R 的菌落数。采用 Tukey-Kramer 分析检验变量之间的关系。具有统计学意义的结果定义为 p≤0.05。

结果

口服给予 3.3×10 CFU 的鼠伤寒沙门氏菌 A1-R 成功消退了裸鼠的 HT1080 肿瘤。然而,较低剂量的 5×10 CFU 则没有观察到这种效果。口服 3.3×10 CFU 鼠伤寒沙门氏菌 A1-R 后,采集肿瘤和肝脏组织,匀浆,在第 3、7 和 14 天进行培养。然后计算 GFP 表达鼠伤寒沙门氏菌 A1-R 的菌落数。口服 GFP 鼠伤寒沙门氏菌后,每隔 3、7 和 14 天从切除的肿瘤中获得的 GFP 细菌菌落数随时间增加。相反,口服 GFP 鼠伤寒沙门氏菌后,从切除的肝脏中可培养的 GFP 鼠伤寒沙门氏菌 A1-R 菌落数随时间减少。此外,从切除的肿瘤中生长的 GFP 细菌菌落明显大于从切除的肝脏中生长的细菌菌落。

结论

本研究表明,口服给予鼠伤寒沙门氏菌 A1-R 可消退侵袭性纤维肉瘤,该菌可准确靶向肿瘤而不会在正常器官中连续生长。本研究结果提示口服鼠伤寒沙门氏菌 A1-R 作为治疗侵袭性软组织肉瘤的益生菌的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbdc/11535920/ee8607a62ad3/in_vivo-38-2602-g0001.jpg

相似文献

4
Tumor-targeting Salmonella typhimurium A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model.
Arch Gynecol Obstet. 2019 Jun;299(6):1683-1690. doi: 10.1007/s00404-019-05147-3. Epub 2019 Apr 5.
6
Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP).
Tissue Cell. 2018 Oct;54:144-149. doi: 10.1016/j.tice.2018.09.001. Epub 2018 Sep 14.
10
Tumor-targeting amino acid auxotrophic Salmonella typhimurium.
Amino Acids. 2009 Sep;37(3):509-21. doi: 10.1007/s00726-009-0261-8. Epub 2009 Mar 17.

本文引用的文献

3
Patient-derived orthotopic xenograft models of sarcoma.
Cancer Lett. 2020 Jan 28;469:332-339. doi: 10.1016/j.canlet.2019.10.028. Epub 2019 Oct 19.
5
Tumor-targeting Salmonella typhimurium A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model.
Arch Gynecol Obstet. 2019 Jun;299(6):1683-1690. doi: 10.1007/s00404-019-05147-3. Epub 2019 Apr 5.
7
Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP).
Tissue Cell. 2018 Oct;54:144-149. doi: 10.1016/j.tice.2018.09.001. Epub 2018 Sep 14.
9
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
Biochem Biophys Res Commun. 2018 Sep 18;503(4):3086-3092. doi: 10.1016/j.bbrc.2018.08.097. Epub 2018 Aug 27.
10
Tumor-targeting A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations.
Heliyon. 2018 Jun 6;4(6):e00643. doi: 10.1016/j.heliyon.2018.e00643. eCollection 2018 Jun.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验